Aspirin
MODEL U-SES: 3-month DAPT noninferior to standard DAPT after PCI with bioresorbable SES
Durable-polymer DES noninferior to polymer-free DCS in patients with high bleeding risk, shorter DAPT: Onyx ONE

SAN FRANCISCO — In the first randomized trial to compare a durable-polymer DES with a polymer-free drug-coated stent in patients with high bleeding risk who received 1 month of dual antiplatelet therapy, treatment with the DES was as safe and effective as treatment with the DCS, according to results of the Onyx ONE trial presented at TCT 2019.
Top stories in cardiology: Shaq discusses heart failure, and some without CVD could benefit from aspirin
VIDEO: Insights on optimal antithrombotic strategy in patients with diabetes, stable CAD
PARIS — In this video exclusive, Deepak L. Bhatt, MD, MPH, executive director of interventional cardiovascular programs at Brigham and Women’s Hospital, professor of medicine at Harvard Medical School and Cardiology Today Editorial Board Member, provides a deep dive on the THEMIS and THEMIS-PCI trials presented at the European Society of Cardiology Congress.